{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-018396","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.972019+00:00","generated_at":"2026-05-16T01:47:26.995813+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"INmune Bio to host Feb 26 webinar on new CORDStrom Phase III data for RDEB","bullets":["Webinar on February 26, 2026 at 1:00 PM ET to present new MissionEB Phase III data for CORDStrom in RDEB.","Focus: systemic disease-modifying therapy beyond topical care, including EBDASI scores, weight gain, pain/itch reduction, and quality of life.","Featured speakers: Dr. Anna Martinez (Principal Investigator) and CSO Prof. Mark Lowdell.","CORDStrom is a patented allogeneic hucMSC cell medicine positioned for inflammatory/autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-018396","json":"https://secwatch.observer/filing/0001213900-26-018396.json","markdown":"https://secwatch.observer/filing/0001213900-26-018396.md","text":"https://secwatch.observer/filing/0001213900-26-018396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026018396/0001213900-26-018396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026018396/ea0277663-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:47:26.995813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}